Pituitary Diseases clinical trials
The registry lists 74 studies for Pituitary Diseases across more than 10 countries. 15 are recruiting or about to start. 18 of them are mainly about Pituitary Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26. Counting its 11 narrower conditions too, such as Dwarfism, Pituitary: 1,015 studies, 166 open.
Get an email when these change. Save the Pituitary Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Corcept Therapeutics (4) · Hospices Civils de Lyon (3) · Novartis Pharmaceuticals (3) · Washington University School of Medicine (2) · Massachusetts General Hospital (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Cedars-Sinai Medical Center (2)
What is being tested here
Drugs under test in Pituitary Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Osilodrostat | 1 | 1 | 3 |
| Human Growth Hormone | 0 | 1 | 3 |
| Mifepristone | 0 | 3 | 3 |
| Pegvisomant | 0 | 1 | 2 |
| Ipilimumab | 0 | 0 | 1 |
| Nivolumab | 0 | 0 | 1 |
| LY2940680 | 0 | 0 | 1 |
| Exenatide | 0 | 0 | 1 |
| Clomiphene | 0 | 0 | 1 |
| Acipimox | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Long Term Outcome Study in Patients With Pituitary Disorders · University of Alberta
- Jul 2027Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome · RECORDATI GROUP
- Nov 2027Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors. · Hospices Civils de Lyon
Who these studies take
Of the 12 Pituitary Diseases studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger. 3 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (17%) | 2 (17%) |
| 18 | 11 (92%) | 11 (92%) |
| 30 | 11 (92%) | 11 (92%) |
| 40 | 11 (92%) | 11 (92%) |
| 50 | 11 (92%) | 11 (92%) |
| 65 | 11 (92%) | 11 (92%) |
| 75 | 10 (83%) | 10 (83%) |
| 85 | 9 (75%) | 9 (75%) |
Across all 74 studies, recruiting or not: 35% stop at 75 or younger and 20% at 65; 27% take children; 1% are for women only and 4% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Radiosurgery for Severe Refractory Cancer Pain: A Sham-Controlled Pilot TrialOct 13, 2026NCT07871123
Studies
Recruiting first, then most recently updated. Showing 50 of 74. Browse all 74 → or search them.
- Study of Endocrine-Related Conditions and PhysiologyRecruitingNCT038674481 country
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsRecruitingNCT06930625Phase 321 countries
- PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary TumoursNot yet recruitingNCT07813351Phase 3
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)RecruitingNCT045432531 country
- Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine DisordersRecruitingNCT078241021 country
- Long-term Follow-up of Pituitary and Hypothalamic Dysfunction in Children Who Have Suffered Moderate to Severe Head Trauma Included in the ENDOC TC CohortNot yet recruitingNCT075334351 country
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromeRecruitingNCT03708900Phase 27 countries
- Postop Pain Management in Pituitary Tumour PatientsRecruitingNCT06353529Phase 41 country
- Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.RecruitingNCT074636251 country
- A Twenty-years' Experience in Pituitary Disease.RecruitingNCT069738241 country
- The Impact of Endoscopic Endonasal Skull Base Surgery on OlfactionRecruitingNCT068744263 countries
- Clinics and Epidemiology of Pituitary Diseases in Modena Area PopulationRecruitingNCT056011411 country
- Clinical-pathological Evaluation of Pit-NETsNot yet recruitingNCT066071981 country
- Clinical Characteristics and Analysis of Pituitary Complex and Rare DiseasesRecruitingNCT064351951 country
- China Pituitary Disease Registry (CAPASITY)RecruitingNCT047132931 country
- Radiosurgery for Severe Refractory Cancer Pain: A Sham-Controlled Pilot TrialTerminatedNCT07871123Not applicable1 country
- Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituitary AdenomasCompletedNCT07763236Not applicable1 country
- A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)CompletedNCT02781727Phase 314 countries
- A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone DeficiencyCompletedNCT03305016Phase 34 countries
- A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical TrialCompletedNCT03344458Phase 311 countries
- Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsCompletedNCT04042753Phase 21 country
- Long Term Outcome Study in Patients With Pituitary DisordersActive, not recruitingNCT03665064
- A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsCompletedNCT05199584Phase 21 country
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)CompletedNCT04897802Phase 41 country
- Safety and Efficacy of Pegvisomant in Children With Growth Hormone ExcessCompletedNCT03882034Phase 31 country
- Age-related Differences in Response to Pituitary Stimulation TestsCompletedNCT045721391 country
- Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)CompletedNCT03636568Not applicable1 country
- Prospective Study of Clinically Nonfunctioning Pituitary AdenomasCompletedNCT015562301 country
- Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)CompletedNCT04902235Phase 41 country
- Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid HemorrhageCompletedNCT006148871 country
- Acromegaly Combination Treatment StudyTerminatedNCT01538966Not applicable1 country
- Changes in the Hypotalamic-pituitary Region of Patients With Metabolic Syndrome and ObesityCompletedNCT034585331 country
- PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic OriginStatus unknownNCT048566831 country
- Pituitary Adenoma and Serum LipidStatus unknownNCT040212121 country
- Ga-68-DOTATOC -PET in the Management of Pituitary TumoursTerminatedNCT02419664Phase 31 country
- The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.CompletedNCT050700911 country
- Radioactive Iodine Implants for Pan-invasive Pituitary MacroadenomasTerminatedNCT01444209Phase 21 country
- Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseCompletedNCT02697734Phase 314 countries
- Setting Benchmarks for Transsphenoidal Resection of Pituitary AdenomasStatus unknownNCT049515571 country
- Clomid in Men With Low Testosterone With and Without Prior TreatmentCompletedNCT01904734Phase 21 country
- Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedNCT01331239Phase 24 countries
- NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop SituationStatus unknownNCT011450401 country
- Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone DeficiencyCompletedNCT00182091Not applicable1 country
- Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone DeficiencyStatus unknownNCT04326374Phase 31 country
- Lipolytic Effects of GH in Hypopituitary Patients in VivoCompletedNCT02782208Not applicable1 country
- Seoul National University Pituitary Disease Cohort StudyStatus unknownNCT034746011 country
- Endocrine and Psychological Evaluation of Adopted ChildrenTerminatedNCT003680431 country
- Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAqCompletedNCT00234533Phase 314 countries
- Transsphenoidal Extent of Resection StudyCompletedNCT02357498Not applicable1 country
- Tolvaptan Versus Fluid Restriction in SIADHCompletedNCT04119206